(Updates Johnson & Johnson filing EUA application)
Feb 5 (Reuters) - Johnson & Johnson has asked U.S. health regulators to authorize its
single-dose COVID-19 vaccine for emergency use and said it will apply to European authorities in
coming weeks. The U.S. FDA will hold a meeting of its Vaccines and Related Biological Products
Advisory Committee on Feb. 26 to discuss the drugmaker's request.
The following table gives the state of play of the main vaccine candidates.
COMPANY STAGE OF DEVELOPMENT EXPECTED DOSES
Pfizer Inc and New Zealand was the latest to (Nine countries for over 600 mln
BioNTech SE authorize the vaccine, with a doses)
total of 15 countries and the EU
having authorized it. South Korea U.S. - 200 mln+ option for 400
has also approved its import. mln more UK - 40 mln; Expects to have 10
mln doses by end of 2020 EU - 600 mln Canada - 40 mln Japan - 120 mln Colombia - 1.7 mln in Feb South Korea - 20 mln Iraq - 1.5 mln Chile - 10 mln Malaysia - 12.8 mln African Union - unspecified (via
COVAX)
Moderna Inc Distribution under way in Canada, U.S. - 200 mln, in talks for
the United States and EU. Delays additional 100 mln
in delivery to Italy, France and
Switzerland. Plans to test new EU - 160 mln
booster shot aimed at the South
African variant. UK - 17 mln Japan - 50 mln or more, to be
distributed by Takeda
Switzerland - 7.5 mln Canada- 40 mln Israel - 6 mln, expects to begin
receiving the vaccines by March
"at the latest" Singapore - Not specified Qatar- Not specified South Korea - 20 mln The Philippines - 20 mln
Johnson & Johnson Applied to the U.S. FDA for U.S. - 100 mln + 200 mln more
authorization of its single-dose under subsequent agreement
COVID-19 vaccine for emergency
use; to apply to European UK - 30 mln + option for up to 22
authorities in coming weeks mln more EU - 200 mln + 200 mln additional Canada - Up to 38 mln Japan - Not Applicable South Korea - 4 mln African Union - unspecified (via
COVAX)
AstraZeneca & Oxford Vaccine approved for emergency (More than 15 countries and
University use by European Medicines Agency groups for over 3 bln doses)
and the UK. India, Pakistan, the
Philippines, South Africa, Chile U.S. - 300 mln
and Brazil have also approved the
shot. Deliveries to EU slowed UK - 100 mln
down.
EU - At least 300 mln + 100 mln
additional Italy, Germany, the Netherlands
and France - 300 mln + 100 mln
additional Canada - Up to 20 mln Japan - 120 mln Bangladesh - 30 mln (through
India's Serum Institute) Colombia - 10 mln South Korea - 20 mln The Philippines - 2.6 mln Malaysia - 6.4 mln India - 11 mln (through Serum
Institute) African Union - unspecified (via
COVAX) plus another 400 million
doses secured
Sinovac Biotech Ltd Turkey and China have granted Indonesia - 125 mln with 1.2 mln
emergency use authorization for doses already secured
the vaccine.
Brazil - in talks for 100 mln
doses Turkey - 50 mln doses (3 mln
received) The Philippines to finalize
negotiations for 25 mln doses Malaysia - 14 mln
Chile - 60 mln doses (first
shipment of nearly 2 mln received
)
Gamaleya Research Institute Filed for registration in Europe; Supply deals with over 13
Russia to conduct trial of a countries including India,
one-dose version; 1.5 mln have Brazil, Algeria, Bolivia and
been inoculated in Russia since Argentina for at least 280 mln
December. Roll out under way in doses.
Belarus and Argentina. Mexico - in talks for 24 mln
doses
CanSino Biologics Inc Approved for use in Chinese Mexico - 10 mln-35 mln doses
military. Late-stage trial under
way in Pakistan and Mexico. China National Pharmaceutical China and Hungary approved the Expects to produce more than 1
Group Corp (Sinopharm) shot developed by an affiliate of bln doses in 2021
Sinopharm. Its efficacy was
pegged at 79.34% by the Pakistan to purchase 1.2 million
company. doses The vaccine has been used on Peru - 38 mln
about 1 mln people in China in an
emergency program.
Bharat Biotech Vaccine granted emergency use In talks with at least 10
authorization in India with countries in South America, Asia
roll-out under way and Eastern Europe
Novavax Inc Europe has begun rolling review, U.S. - 100 mln
Company has applied to Canada for
review. Prelim data from UK - 60 mln
late-stage UK trial shows vaccine
is 89.3% effective in preventing Canada - Up to 76 mln
COVID-19 and equally effective
against UK variant; Late-stage Japan - 250 mln
study under way in the U.S. and
Mexico. Australia - 51 mln + option for
additional 10 mln; initial doses
expected by mid-2021 The Philippines - 30 mln by July
2021 Indonesia - 30 mln New Zealand - 10.7 mln EU - In negotiations Medicago Begins mid-to-late stage studies No supply deals yet
of its experimental vaccine in
combination with a booster from
GlaxoSmithKline .
Anhui Zhifei Longcom Begins Phase III trials, planning No supply deals yet
Biopharmaceutical to recruit 29,000 volunteers
across the world (bit.ly/3mc5WUI)
(Reporting by Amruta Khandekar, Dania Nadeem, Mrinalika Roy, Vishwadha Chander, Manas Mishra,
Trisha Roy, Muvija M and Pushkala Aripaka in Bengaluru; Editing by Anil D'Silva and Arun Koyyur)
我们的标准: 汤森路透“信任原则”